Mode
Text Size
Log in / Sign up
Phase 4 N=17 Randomized Quadruple-blind Treatment

Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain

Pain, Intractable · Breakthrough Pain · Chronic Pain

Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Mar 2022
Primary outcome: Primary: Change From Baseline in the Numerical Rating Pain Scale (NRS) — 1.87; 1.81 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Bupivacaine (Drug); Opioid (Drug)
Age
Adult, Older Adult · 31+ yrs
Sex
All
Sponsor
University Hospitals Cleveland Medical Center
Primary completion
Dec 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in the Numerical Rating Pain Scale (NRS)
1.87; 1.81
SECONDARY
Change From Baseline in Oswestry Disability Index (ODI)
.88; 2.67
SECONDARY
Change From Baseline in Patient Global Impression of Change (PGIC)
-0.06; 1.25
SECONDARY
Change From Baseline in painDETECT
0.69; 0.25
SECONDARY
Change From Baseline in Average Weekly Numeric Pain Rating Score (NRS)
-0.47; -0.38
SECONDARY
Change From Baseline in Treatment Satisfaction
2.36; 1.94

Summary

The purpose of this study is to determine whether the local anesthetic bupivacaine delivered intrathecally in small doses via PTM self-administered boluses significantly improves the breakthrough pain and functional status of patients with chronic intractable pain who are managed with an intrathecal drug delivery system.

Eligibility Criteria

Inclusion Criteria

  • Age more than 30 years implanted with an intrathecal drug delivery device.
  • Intrathecal pump patients on stable dose for the last 3 months.
  • Using on average more than 2 and less than 10 PTM doses per day
  • Intrathecal medication admixture consisting of bupivacaine and another opioid (fentanyl or hydromorphone or morphine)

Exclusion Criteria

  • Using 10 or more PTM bolus doses per day or 2 or less PTM bolus doses per day
  • Pending litigation or worker compensation claim
  • Any recent (less than 3 month) procedures in spine (surgeries) or catheter adjustments.
  • Recent pump dose adjustment within the past 3 months
  • Pumps with medications other than bupivacaine/opioid combination.
  • Pregnant or breast feeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02886286). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search